Inotuzumab ozogamicin, a nonchemotherapy option for relapsed acute lymphoblastic leukemia.

Inotuzumab ozogamicin, a nonchemotherapy option for relapsed acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2019 May;17(5):268-270 Authors: Kantarjian HM PMID: 31188803 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/31188803?dopt=Abstract

Source: Clinical Advances in Hematology and Oncology - June 14, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer & Oncology | Hematology | Leukemia